银诺医药-B(02591.HK)：依苏帕格鲁肽α在澳门正式进入商业化销售

Core Viewpoint - The company is actively advancing the global expansion of its core product, Isupravaglutide α, which has recently received regulatory approval for the treatment of Type 2 Diabetes (T2D) in Macau [1]. Product Development - The company announced that on September 12, 2025, the first prescription for its core product for T2D was issued at the Huabao Medical Center in Macau, marking the official commercialization phase of the product in the region [1]. - The Biologics License Application (BLA) for the core product was approved in Macau on June 2025, indicating a significant milestone in the product's development [1].